Diabetes Devices Market 2025 Growth & Forecast

The global diabetes devices market was valued at USD 20.92 billion in 2018 and is expected to grow to USD 48.35 billion by 2032, with a compound annual growth rate (CAGR) of 6.2% throughout the forecast period. In 2018, North America led the market, holding a share of 40.54%.

The growth of the global diabetes care devices market is primarily driven by the rising incidence of diabetes, which is linked to sedentary lifestyles and rapid urbanization. Technological advancements in blood glucose monitoring systems and minimally invasive insulin delivery devices have led to an increase in the number of diabetes diagnoses worldwide. For example, in September 2017, Abbott received FDA approval for the FreeStyle Libre Flash Glucose Monitoring System. This device features a small sensor placed on the upper arm to monitor blood glucose levels.

Get a Free Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-devices-market-100803

Diabetes Devices Market Segmentation:

By Type Analysis

The global diabetes devices market is segmented into monitoring and treatment devices. The monitoring devices segment held the largest share in 2018 and is expected to grow faster during the forecast period. This growth is driven by increasing regulatory approvals for continuous blood glucose monitoring systems and advancements in insulin delivery devices like smart insulin patches, inhalers, and closed-loop pump systems. The rising adoption of wearable monitoring systems and smart insulin pumps for self-management also supports this growth.

By Distribution Channel Analysis

The market is divided into retail and institutional sales. The retail sales segment is expected to grow at a higher rate due to the increasing availability of private-label brands at discounted prices in retail outlets. Additionally, the rising prevalence of chronic diseases and surgeries is boosting demand for blood glucose meters, which will drive institutional sales during the forecast period.

List Of Key Companies Covered in Diabetes Devices Market:

• F. Hoffmann-La Roche Ltd

• Tandem Diabetes Care, Inc.

• B. Braun Melsungen AG

• Medtronic

• BD

• Novo Nordisk A/S

• Abbott

• Sanofi

• Other players

Diabetes Devices Market Drivers:

Market Growth Driven by Innovative Products

The global diabetes devices market is expanding due to the introduction of new products. For instance, in 2019, Tandem Diabetes Care received FDA approval for the t:Slim X2 insulin pump, and Bigfoot Biomedical partnered with Eli Lilly to develop AI-based insulin delivery solutions. Additionally, Amazon launched a medical device brand focused on diabetes, offering blood glucose and blood pressure monitors with mobile app support, increasing awareness and demand for diabetes devices.

Rising Diabetes Prevalence Boosts Demand

The rising prevalence of diabetes, particularly in countries like China and India, is driving the demand for monitoring and treatment devices. With over 425 million adults affected by diabetes in 2017, projected to rise to 630 million by 2045, the increasing rates of obesity and lack of awareness are further fueling the market for diabetes management devices globally.

Regional Analysis:

In 2018, North America generated USD 8.48 billion in revenue and is expected to grow at a moderate CAGR. Europe's growing diabetes population and lower prices of insulin and delivery devices are driving market growth. Asia Pacific is projected to grow at a higher CAGR due to the rising diabetic population, increased adoption of advanced blood glucose meters, and higher demand for insulin delivery devices. The Middle East, Africa, and Latin America are also expected to experience significant growth, fueled by a rising diabetic population, increased healthcare investment, and growing awareness of disease diagnosis and monitoring.

Key Industry Developments:

• May 2021 – Medtronic received European approval for two diabetes management devices: the InPen, a connected insulin pen for those requiring multiple daily injections, and the Guardian 4 sensor, which can be used as a standalone continuous glucose monitor or with the InPen. Both devices are CE marked.

• March 2021 – Roche launched the new Accu-Chek Instant system, featuring Bluetooth connectivity to the mySugr app, allowing seamless transfer of blood glucose results. This system aligns with Roche’s patient-centered approach to personalized diabetes management.

• June 2020 – Abbott and Tandem Diabetes Care finalized an agreement to develop integrated diabetes solutions, combining Abbott's continuous glucose monitoring (CGM) technology with Tandem's insulin delivery systems, offering more options for diabetes management.